Onkologie. 2015:9(2):74-80

Eribulin mesylate (Halaven®): a new hope for pretreated patients with advanced and metastatic breast cancer

Jitka Abrahámová, Zuzana Donátová
Onkologická klinika 1. LF UK a Thomayerovy nemocnice Praha

Eribulin is a non-taxane microtubule dynamics inhibitor. It is a synthetic analogue of halichondrin B. By acting on microtubules, eribulin

has an antimitotic effect in the G2/M phase of cell cycle, disrupting the mitotic spindle and inducing apoptosis. It specifically inhibits

the growth phase of microtubules and sequesters tubulin in non-productive aggregates. Recently, the results of preclinical research

of “non-mitotic” mechanism of action of eribulin (particularly the effect on tumour vascularization, epithelial-mesenchymal transition,

invasiveness, and migration ability) have been published.

Keywords: advanced and metastatic breast cancer, eribulin, phase III trials 305,301

Published: April 10, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Abrahámová J, Donátová Z. Eribulin mesylate (Halaven®): a new hope for pretreated patients with advanced and metastatic breast cancer. Onkologie. 2015;9(2):74-80.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Novotvary 2011, ÚZIS, Praha 2015.
    2. Yoshida T, Ozawa Y, Kimura T, et al. Eribulin mesylate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition MET states. British Journal of Cancer 2014: 1-9. Go to original source...
    3. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61: 1013-1021.
    4. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009; 27: 2954-2961. Go to original source... Go to PubMed...
    5. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28: 3922-3928. Go to original source... Go to PubMed...
    6. Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 2012; 23(6): 1441-1448. Go to original source...
    7. Cortes J, O'Shaughnessy J, Loesch D, et al., Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377(6769): 914-923. Go to original source...
    8. Kaufman PA, Cortes J, Awada A, et al. A phase III, open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes: Subgroup analyses. SABCS 2010, poster 1049. Go to original source...
    9. Kaufman PA, Awada A, Twelves Ch, et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. SABCS 2012, presentation S6-6. Go to original source...
    10. Twelves Ch. Trials and tribulations of cytotoxic and targeted breast cancer trerypy: a clinical perspective on the next phase of progress. Expert Rev. Anticancer Ther. 2013; 13(3): 251-255. Go to original source... Go to PubMed...
    11. Blum JL, Twelves CJ, Dutcus C, et al. Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) Among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study. SABCS, Abstract no. P6-13-01, 2010. Go to original source...
    12. La Verde N, Piva S, Ganzinelli M, et al. Tumor Shrinkage and improved quality of life in a heavily pretreated metastaic breast cancer patient treated with eribulin. Future Oncol. 2013; 9(11): 1703-1709. Go to original source...
    13. Velikova G, Hudgens S, Forsythe A, et al. Health-related quality if life (HRQoL) and disease symptoms in patients with locally advanced or metastatic breast cancer (MBC) treated with eribulin or capecitabine in a post anthracycline and taxane setting. ASCO Poster N. 392P, 2014. Go to original source...
    14. Pashaj E, Cortesi L, Proietto M, et al. A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate. Future Oncol. 2013; 9(10), 1437-1442. Go to original source...
    15. Patridge AH, Rumble RB, Carey LA, Et al. Chemotherapy and targeted therapy for woman with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical onkology clinical practice guideline. J Clin Oncol 32, 2014. Go to original source...
    16. McBride A, Butler SK, Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer. Am J Health-Syst Pharm - Vol. 69 May 1, 2012. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.